Intrinsiqq
Johnson & Johnson logo

Johnson & Johnson Quality Score

JNJ

⊜ Compare
Quality53

Valuation is the primary weakness (avg 40/100). No single area scores well.

Broad-market heuristics · Not a buy/sell signal

Valuation and growth

Earnings Multiple
40/100
42.0x

Above 30x, priced for sustained outperformance

Cash Flow Multiple
40/100
32.3x

Above 30x, cash flow yield is thin

Revenue Growth
70/100
5.6%

5–10% CAGR, steady but not exceptional

Cash Flow Growth
50/100
4.6%

2–5% CAGR, growing but slowly

Business Quality & Capital Allocation

Share Dilution
100/100
-8.1%

Shrinking >2%, active buybacks

Margin Trend
20/100
-0.6pp

Modest contraction, within normal range

Capital Structure
40/100
$27.42B

Net debt/FCF of 1.3x, somewhat elevated

2023
$23.5B
$42.5B
2023
$22.9B
$31.9B
2024
$24.5B
$39.6B
2025
$20.1B
$51.3B
TTM
$17.2B
$44.6B
CashDebt
Return on Capital
80/100
18.1%

15–20%, well above cost of capital

Customize WeightsPremiumUpgrade

Johnson & Johnson (JNJ) quality: score, margins and returns

Johnson & Johnson (JNJ) scores 53/100 on Intrinsiqq's quality score (a mixed business), a weighted blend of 8 metrics each scored 0 to 100, on 25.7% operating margins and 18.1% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Johnson & Johnson (JNJ) a high-quality business?+

Johnson & Johnson scores 53 out of 100 on Intrinsiqq's quality score, a weighted blend of 8 metrics each scored 0 to 100, which rates it a mixed business on these measures. Recent figures include a 25.7% operating margin and a 18.1% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.

What does Johnson & Johnson's quality score measure?+

Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from JNJ's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where Johnson & Johnson scores well and where it falls behind.

What is Johnson & Johnson's return on invested capital (ROIC)?+

Johnson & Johnson earns about 18.1% on its invested capital, which is strong. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to JNJ's margins and growth on this scorecard to judge durability.

How profitable is Johnson & Johnson?+

Johnson & Johnson runs an operating margin of about 25.7% and a net margin of about 16.2%. Revenue has grown at roughly 2.7% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.

How the market compares: US profitability statistics

SourceQuality score computed from the 10-Q filed 15 Oct 2026, covering the period ending 27 Sept 2026, as reported to the SEC. Data last refreshed 22 Oct 2026. How this is calculated.

Fiscal year ends Jan. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.

Peers

Pharmaceutical Preparations · Pick stocks to compare with JNJ

CompareIntrinsic value
LLYEli Lilly and Company
$1,418.07+0.62%73
MRKMerck & Co., Inc.
$150.36+3.93%41
ABBVAbbVie Inc.
$294.83+3.09%49
PFEPfizer Inc.
$30.79+2.63%30
BMYBristol-Myers Squibb Company
$64.20+4.04%61
ABTAbbott Laboratories
$115.55+5.62%25
UPCUniverse Pharmaceuticals Inc.
$1.47-1.34%39
TEVATeva Pharmaceutical Industries Ltd
$42.13+0.52%46

Held by ETFs

JNJ is in 485 US ETFs. The largest of them, with JNJ's weight in each:

Spot a number that looks wrong? Check it in JNJ's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing JNJ

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.